1. Home
  2. FEAM vs GANX Comparison

FEAM vs GANX Comparison

Compare FEAM & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo 5E Advanced Materials Inc.

FEAM

5E Advanced Materials Inc.

HOLD

Current Price

$1.57

Market Cap

70.2M

Sector

Industrials

ML Signal

HOLD

Logo Gain Therapeutics Inc.

GANX

Gain Therapeutics Inc.

HOLD

Current Price

$1.64

Market Cap

78.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FEAM
GANX
Founded
2016
2017
Country
United States
United States
Employees
35
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
70.2M
78.2M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
FEAM
GANX
Price
$1.57
$1.64
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
4
Target Price
$6.38
$7.50
AVG Volume (30 Days)
240.3K
688.3K
Earning Date
05-20-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
31.46
EPS
N/A
N/A
Revenue
N/A
$55,180.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.17
$1.41
52 Week High
$7.50
$4.34

Technical Indicators

Market Signals
Indicator
FEAM
GANX
Relative Strength Index (RSI) 41.67 40.28
Support Level $1.45 N/A
Resistance Level $1.80 $2.10
Average True Range (ATR) 0.17 0.13
MACD -0.04 -0.01
Stochastic Oscillator 6.90 17.35

Price Performance

Historical Comparison
FEAM
GANX

About FEAM 5E Advanced Materials Inc.

5E Advanced Materials Inc is an exploration stage company focused on becoming a vertically integrated supplier of specialty boron and boron derivative materials whose mission is to enable decarbonization, increase food security, and ensure domestic supply of critical materials. It has a project located in southern California underpinned by a mineral resource that includes boron and lithium, with the boron being contained in a conventional boron mineral known as colemanite. The company seeks to extract and process the minerals into boric acid, boron materials, lithium carbonate, and potentially other co-products on a commercial scale.

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.

Share on Social Networks: